Temedica Introduces Permea: First Analytics Platform Integrating Patient-Generated Health Data

ACM Presents PEARC22, July 10–14, in Boston

The ACM PEARC22 (Association of Computing Machinery, Practice and Experience in Advanced Research Computing) conference will be held at the Boston Park Plaza Hotel in Boston, Massachusetts, July 10–14, 2022.

Topography Health Launches with $27.5M Funding to Empower Community Physicians to Run Clinical Drug Trials

Topography Health, the world’s first full-stack clinical trials platform for community physicians, launched out of stealth this week to tackle mass scale clinical trial access: Backed by Bain Venture Capital and Andreesen Horowitz with $27.5M in funding, Topography is on a mission to expand access to clinical trials for both patients and their providers. By creating the largest network of community physicians and equipping them with the tools and staff they need to conduct medical research, Topography is making it possible for your family doctor to offer clinical drug trials as part of their practice. Research will not just be for potentially terminal illnesses, but also for moderate chronic illnesses, where the standard of care lags.

CD Formulation: Customized Preparation of Active Pharmaceutical Ingredient Excipients to Accelerate Drug Formulation Projects

Quantum Dots & Upconverting Nanoparticles Provided by Alfa Chemistry Can Improve Medical Technology and Energy Research

Microarray Data Analysis Service Now Available by CD Genomics's Bioinformatics-Analysis Platform

The Bioinformatics-analysis division is a new division of CD Genomics that provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. Recently, CD Genomics announced the launch of the Microarray Data Analysis service to help scientists discover the biological significance of microarray data and, at the same time, help reduce the time and cost of wet laboratory experiments and data generation.

Biomedical Bioinformatics Platform Unveils Biomarker and Target Discovery Data Analysis Service

The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the launch of biomarker and target discovery service for disease identification, early diagnosis and prevention, and monitoring during treatment.

BioIVT Launches GMP Grade Human AB Serum to Facilitate the Development and Manufacturing of Cell and Gene Therapies

This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies.

WuXi STA Launches its First Parenteral Formulation Manufacturing Line

DxCG Intelligence Celebrates 25th Anniversary, Launches Version 6.0 with Enhanced Clinical and Pharmaceutical Classification Systems

Cotiviti’s preeminent risk assessment and predictive modeling tool continues to aid in improving healthcare cost and quality

Protecting All Assets from All Cyber Attacks Is Unrealistic; Focus on Preventing the Unacceptable: Positive Technologies CEO

In a talk at the World Expo 2020 Dubai on Sunday, Positive Technologies CEO, Denis Baranov spoke about how protecting all assets from all cyberattacks is unrealistic, and suggested that organizations and industries instead take a new approach that specifically focuses on eliminating ‘unacceptable’ risks at every level.

CD ComputaBio Unveils Ligand-based Pharmacophore Model Service for Drug Design and Screening

CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the drug candidate development process.

Creative Proteomics Lipidomics Launches Exosomes Lipidomics Service to Study the Biological Characteristics of Vesicles

Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population health, the food industry, etc. Creative Proteomics Lipidomics has recently announced the launch of Exosomes Lipidomics Service, which can help scientists understand vesicle biogenesis and function, identify lipid-based biomarkers and unravel their monitoring function in diseases.

GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota

Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis

Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data.

Amerigo Scientific Launches Polycaprolactone for Bioprinting

Amerigo Scientific introduces Polycaprolactone for research uses.

STEMart Introduces Chemical Characterization for Medical Device Industry

STEMart launches chemical characterization services for the medical device industry.

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception.

Positive Technologies Names Top 10 Phishing Topics of 2021

Positive Technologies today issued a new study that outlines the top 10 phishing topics used by cybercriminals throughout 2021, including: • New TV shows and movies • Banking issues • Travel and vacation • Dating • And cryptocurrency investments

Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis